Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.

ABSTRACT:

Importance

Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression.

Objective

To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode.

Design, setting, and participants

This was a 12-week, open-label nonrandomized open-label trial conducted at Sheppard Pratt Hospital. Participants aged 18 to 65 years with BDII, a current depressive episode longer than 3 months, and documented insufficient benefit with at least 2 pharmacologic treatments during the current episode were invited to participate. Of 70 approached, 19 met inclusion criteria and we

SUBMITTER: Aaronson ST 

PROVIDER: S-EPMC10701666 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature